Immunovia
Immunovia AB is a Swedish molecular diagnostics company focused on the development and commercialization of blood-based test diagnostics for early cancer detection. The company utilizes its proprietary IMMray microarray platform to develop advanced blood tests designed for the early detection of pancreatic cancer and other complex malignancies. Its core operations encompass biomarker discovery, immunoassay development, clinical validation studies, and laboratory testing services. As a diagnostic development enterprise, the company generates initial commercial revenue while primarily funding its ongoing research through capital markets and partnership funding. Immunovia holds a specialized position in early cancer detection diagnostics. The company is headquartered in Lund, Sweden, and its shares trade on Nasdaq Stockholm.
3 of the funds FundTelligence covers report a position in Immunovia.
- Legal name
- Immunovia AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 3
Funds holding Immunovia
- Handelsbanken Norden Index Criteria — Handelsbanken · 0.0 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Småbolag Plus — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.0 % (full portfolio disclosed, October 2026)